Antibody therapy of acute myelogenous leukemia Journal Article
| Author: | Jurcic, J. G. |
| Article Title: | Antibody therapy of acute myelogenous leukemia |
| Abstract: | Monoclonal antibodies (mAbs) have become an important modality for cancer therapy. A genetically engineered, humanized anti-CD33 antibody HuM195 has demonstrated activity against overt relapsed acute myelogenous leukemia (AML) and against minimal residual disease in acute promyelocytic leukemia (APL). Radioimmunotherapy with beta (β) particle-emitting isotopes has produced significant responses while minimizing radiation exposure to normal tissues in both nonmyeloablative and myeloablative regimens. Targeted alpha (α) particle therapy with 213Bi-labeled HuM195 offers the possibility of more selective tumor cell kill. Additionally, directed chemotherapy using an anti-CD33-calicheamicin conjugate (CMA-676) has produced remissions in patients with relapsed AML. |
| Keywords: | unclassified drug; acute granulocytic leukemia; review; radiopharmaceuticals; animals; antineoplastic activity; radiation exposure; monoclonal antibody; cancer regression; antibodies, monoclonal; anti-bacterial agents; acute myeloblastic leukemia; radioimmunotherapy; radioisotopes; clinical trials; gemtuzumab ozogamicin; electron; alpha radiation; aminoglycosides; immunoconjugates; bismuth; hum 195; immunization, passive; leukemia, myelocytic, acute; humans; human; priority journal |
| Journal Title: | Cancer Biotherapy and Radiopharmaceuticals |
| Volume: | 15 |
| Issue: | 4 |
| ISSN: | 1084-9785 |
| Publisher: | Mary Ann Liebert, Inc |
| Date Published: | 2000-08-01 |
| Start Page: | 319 |
| End Page: | 326 |
| Language: | English |
| PUBMED: | 11041016 |
| PROVIDER: | scopus |
| DOI: | 10.1089/cbr.2000.15.319 |
| DOI/URL: | |
| Notes: | Export Date: 18 November 2015 -- Source: Scopus |
